What is the first‑line antibiotic for prophylaxis in HIV‑infected patients?

First-Line Antibiotic Prophylaxis in HIV-Infected Patients

Trimethoprim-sulfamethoxazole (TMP-SMX) double-strength tablet (160 mg TMP/800 mg SMX) taken once daily is the first-line antibiotic for prophylaxis in HIV-infected patients with CD4 counts below 200 cells/µL. 1, 2

Primary Indication and Initiation Criteria

• Start TMP-SMX prophylaxis when CD4 count falls below 200 cells/µL, regardless of symptoms or antiretroviral therapy status. 1, 3
• Initiate prophylaxis immediately if the patient has oropharyngeal candidiasis or unexplained fever >100°F for ≥2 weeks, even if CD4 is above 200 cells/µL. 1
• Begin prophylaxis when CD4 percentage is <14%, even if absolute CD4 count is >200 cells/µL. 2

Preferred Dosing Regimen

• TMP-SMX double-strength tablet (800 mg SMX/160 mg TMP) once daily, 7 days per week is the preferred regimen. 1, 2
• Alternative acceptable dosing: Single-strength tablet once daily (may be better tolerated with comparable efficacy). 1
• Second alternative: Double-strength tablet three times weekly (Monday, Wednesday, Friday) if daily dosing is not feasible. 3, 4

Rationale for TMP-SMX as First-Line

• TMP-SMX provides simultaneous protection against three major opportunistic infections: Pneumocystis jirovecii pneumonia (PCP), toxoplasmosis (in seropositive patients), and common bacterial respiratory infections. 1, 2, 5
• Superior efficacy compared to alternatives: In comparative trials, TMP-SMX reduced bacterial infections by 20-30% compared to dapsone or aerosolized pentamidine. 5, 6
• Reduces infectious diarrhea, sinusitis/otitis media, and pneumonia more effectively than other prophylactic agents. 6
• Provides cross-protection against Haemophilus species, Salmonella, Staphylococcus, and toxoplasmosis. 5

Alternative Regimens (for TMP-SMX Intolerance Only)

For PCP Prophylaxis Only (No Toxoplasmosis Coverage)

• Dapsone 100 mg orally once daily – first-line alternative. 1, 2
• Atovaquone 1500 mg orally once daily – effective but substantially more expensive. 2, 7
• Aerosolized pentamidine 300 mg monthly via Respirgard II nebulizer – least preferred; provides no systemic or toxoplasmosis protection. 1, 2

For Combined PCP and Toxoplasmosis Coverage (TMP-SMX Intolerant, Toxoplasma-IgG Positive, CD4 <100 cells/µL)

• Dapsone 50 mg daily + pyrimethamine 50 mg weekly + leucovorin 25 mg weekly – provides dual protection. 1, 2

Managing TMP-SMX Adverse Reactions

• For non-life-threatening reactions (mild rash, low-grade fever, mild cytopenias): Continue TMP-SMX if clinically feasible rather than switching to less effective alternatives. 1, 3, 7
• Up to 70% of patients can tolerate TMP-SMX rechallenge using gradual dose escalation (desensitization) protocols. 3, 7
• Consider reducing dose or frequency (single-strength daily or double-strength three times weekly) before abandoning the drug. 3, 4
• Permanently discontinue TMP-SMX only for life-threatening reactions: Stevens-Johnson syndrome, toxic epidermal necrolysis, severe bone marrow suppression, or anaphylaxis. 3, 8

Duration and Discontinuation Criteria

• Continue prophylaxis lifelong unless immune reconstitution occurs with effective antiretroviral therapy (ART). 2, 3, 7
• Discontinue prophylaxis only when CD4 count rises above 200 cells/µL and remains stable for at least 3 consecutive months on ART with sustained viral suppression. 2, 3
• Restart prophylaxis immediately if CD4 count subsequently falls below 200 cells/µL. 2, 3

Special Populations

Pregnant Women

• Pregnant HIV-infected women should receive TMP-SMX prophylaxis using the same CD4 criteria as other adults. 1
• During the first trimester, clinicians may substitute aerosolized pentamidine due to theoretical teratogenicity concerns with TMP-SMX, though this is a weaker recommendation. 1

Infants and Children

• Infants born to HIV-infected mothers should start TMP-SMX at 4-6 weeks of age and continue through the first year of life, regardless of HIV infection status. 1, 3
• HIV-infected children should continue prophylaxis after the first year based on age-specific CD4 thresholds. 1

Critical Clinical Pitfalls to Avoid

• Do not delay initiation when CD4 <200 cells/µL; the risk of life-threatening opportunistic infections is extremely high. 2, 3
• Do not abandon TMP-SMX for minor adverse reactions without first attempting desensitization or dose modification. 3, 7
• Do not use aerosolized pentamidine as first-line prophylaxis when TMP-SMX is tolerated; it lacks systemic coverage and does not prevent toxoplasmosis. 2, 3
• Do not discontinue prophylaxis based on a single CD4 measurement; sustained elevation for ≥3 months is mandatory. 2, 3
• Do not prescribe TMP-SMX indiscriminately when prophylaxis is not indicated, to avoid fostering drug-resistant organisms. 8

Additional Monitoring Considerations

• Monitor complete blood count monthly in patients on chronic TMP-SMX, as hematologic toxicity increases with duration of therapy. 3, 8
• Ensure adequate fluid intake to prevent crystalluria and stone formation. 8
• In AIDS patients, the incidence of side effects (rash, fever, leukopenia, elevated liver enzymes) is greatly increased compared to non-AIDS patients. 8
• Close monitoring of serum potassium is warranted in patients with renal insufficiency or those taking drugs that induce hyperkalemia. 8